However, given that we did not know patients' PLA2R1 status at inclusion (antibodies not routinely tested at the time the study was set up) and until the end of follow-up (centralized antibody assay in sera at day 0), we were unable to analyze a cohort consisting solely of patients with anti-PLA2R1-associated membranous nephropathy. Here, PLA2R1 is linked to membranous glomerulonephritis.